Trial Profile

Study of TTX-MC138 for the Treatment of Patients with Metastatic Breast Cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TTX-MC138 (Primary)
Indications Breast cancer
Focus Adverse reactions

Most Recent Events

26 Jun 2023 New trial record
22 Jun 2023 Results published in a TransCode Therapeutics Media Release.
22 Jun 2023 According to TransCode Therapeutics Media Release, the company announced publication of new data relevant to TTX-MC138, in the Journal of Clinical Oncology.The abstract, published in the June 1 supplemental issue of the journal, was presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com